Fulwood Place, where our office is located, is a narrow alley off High Holborn, with a Japanese barbeque restaurant Kintan at the corner. Currently, the building where Kintan is located is covered in scaffolding, which partially obscures the entrance to Fulwood Place.
From Chancery Lane Station (Central Line)
Approx. 5–6 minutes’ walk
Exit the station via Exit 4 – High Holborn (North Side).
Continue straight (west direction) on High Holborn in same direction as the station exit.
Walk straight until you reach Fulwood Place on your right, a narrow alley with restaurant Kintan at the corner.
After a short walk through the narrow alley— our building, Fairfax House, will be on your right.
From Holborn Station (Central & Piccadilly Lines)
Approx. 7–8 minutes’ walk
If you leave Holborn station via main exit, you step onto Kingsway
Turn right to reach High Holborn and turn right onto High Holborn.
(Alternatively, there is a subsidiary station exit that leads directly onto High Holborn, in which case turn right out of the station)
Keep walking along High Holborn (east direction).
Continue straight until you reach Fulwood Place on your left, a narrow alley with restaurant Kintan at the corner.
After a short walk through the narrow alley— our building, Fairfax House, will be on your right.
From Farringdon Station (Elizabeth, Circle, Hammersmith & City, Metropolitan + National Rail)
Approx. 12–15 minutes’ walk
Exit Farringdon Road, and you step into Cowcross Street.
Turn left out of station if you come from EL or NR, and right if you come out of tube station for other lines.
Turn left onto Farringdon Road (south direction) and after about 100m bear right into Charterhouse Street.
After another 100m bear right onto Holborn (west direction).
After passing the junction with Gray's Inn Road, Holborn becomes High Holborn.
Continue straight until you reach Fulwood Place on your right, a narrow alley with restaurant Kintan at the corner.
After a short walk through the narrow alley— our building, Fairfax House, will be on your right.
Taxi / Ride‑Share Drop‑Off
Ask to be dropped at:
“Fulwood Place, WC1V 6HU — near High Holborn.”
Our entrance is on the right‑hand side as you walk down Fulwood Place.
Accessibility Notes
Farringdon Station offers full step‑free access from street to train (Elizabeth Line, Thameslink, and some Underground services).
The walk from Farringdon provides the smoothest route if mobility support is required.
If you need assistance on arrival, our reception team is available Monday–Sunday, 8:00–18:00 (open on bank holiday as well)
The Latest Thought Leadership pieces in the Content Hub
INTA 2026 Essentials: Where to stay, what to see and what to do
June 3, 2025
Discover the INTA 2026 Essentials! This comprehensive guide will help you navigate your stay, showcasing the best accommodations, must-see attractions, and exciting activities to enjoy during your visit.
Oops! Something went wrong while submitting the form.
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.